

Mike Burgess is BMS's head of discovery medicine

January 22, 2013 | News | By BioSpectrum Bureau



Singapore: Bristol-Myers Squibb (BMS) appointed Dr Mike Burgess as senior vice president, discovery medicine and clinical pharmacology, BMS. He will report to Dr Francis Cuss, senior vice president, R&D, BMS, and will be a member of the research senior leadership team.

Before joining Bristol-Myers Squibb, Dr Burgess was interim head of Hoffman La-Roche's pharma research and early development business. Prior to that he led the Hoffman La-Roche Oncology Discovery and Translational team, and also served as the head of global large molecule research at the same time.

Before joining Hoffman La-Roche, Dr Burgess worked with Eli Lilly and Company as a medical fellow. He received his medical training and PhD from the University of Bristol, UK, and is a member of the Royal College of Physicians and of the Royal College of Pediatrics and Child Health.

Dr Cuss said that, "As a physician scientist with a PhD in molecular biology, clinical experience in pediatrics and pediatric oncology, and extensive pharmaceutical industry and leadership experience, I believe Mike will be an important addition to our research and development organization. Mike's broad clinical expertise, cross-therapeutic global team leadership and proven operational excellence will enable Bristol-Myers Squibb to continue to execute its strategy of ensuring sustainable delivery of an innovative pipeline of new medicines for patients."

Dr Burgess said that, "I am excited by the opportunity to join Bristol-Myers Squibb and its research leadership team. Bristol-Myers Squibb is well known and respected for its innovative pipeline and approach to discovering and developing new medicines. I am looking forward to joining this committed team and continuing to drive research that delivers a differentiated pipeline of potential new medicines."